NCT06315972View on ClinicalTrials.gov

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

April 30, 2028

Conditions

Schizophrenia

Interventions

DRUG

clemastine (8 mg/day)

add-on clemastine (8 mg/day) + aerobic exercise training

DRUG

Placebo

add-on placebo + aerobic exercise training

All Listed Sponsors

lead

LMU Klinikum

OTHER